News

GSK's investigational Ebola vaccine is in Phase I safety trials.

Unum Therapeutics raised $12 million in Series A funding for its development of antibody-coupled T cell receptors (ACTRs) for the treatment of nonspecific tumor cells.

A customer complaint prompts the recall of a lot of anticoagulants from a plant in Puerto Rico.

Johnson& Johnson is collaborating with WHO and others on clinical testing, development, production, and distribution of an Ebola vaccine.

Contract Packaging Resources issued a voluntary recall of naproxen sodium tablets because some cartons contain bottles of ibuprofen.

Ashland Specialty Ingredients opened a drug development and bioavailability enhancement facility in Wilmington, Delaware.

The renovation to Roche's historic office building in Basel, Switzerland will feature sustainable workplaces and a state-of-the-art research center.

FDA approved a Cook Pharmica facility and a Patheon facility for manufacturing of Halozyme products.

AbbVie to pay Shire $1.635 billion break fee for terminating purchase agreement.

The agency recommends that companies developing drugs to treat Ebola apply for orphan drug designation.

Lilly announces the closure of its Guayama, Puerto Rico manufacturing facility amid continued investments at other plants.

Personalized immunotherapy treatments help 90% of acute lymphoblastic leukemia patients achieve remission in a new study.

Boehringer Ingelheim's OFEV was approved by FDA as the first treatment for idiopathic pulmonary fibrosis, a fatal lung disease.

Genentech announced FDA-approved Esbriet for the treatment of Idiopathic Pulmonary Fibrosis.

Pfizer's addition of a new vaccine suite and multiproduct bioprocess suite to its Ireland facility win the company the title of 2014 Facility of the Year.

The company submits an orphan drug application to FDA for its Cell-in-a-Box treatment for pancreatic cancer.

Sanofi Pasteur and Immune Design agree to jointly develop therapies through Phase II clinical trials.

BioReliance has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services its service offering. The company#&39;s range of predictive assays use a novel suite of genetically modified cell lines created with CompoZr zinc finger nuclease (ZFN), a Sigma-Aldrich proprietary technology.

AbbVie sends Shire notice that it is reconsidering its offer recommendation.

The International Society for Pharmaceutical Engineering (ISPE) released its Drug Shortages Prevention Plan as part of an initiative to address drug shortage prevention due to manufacturing and quality issues.

Vetter's clinical manufacturing services continue to attract new business.

Hospira voluntary recalls certain lots of several LifeCare products due to potential for leakage.

The Pharmaceutical Research and Manufacturers of America released their 2014 Cancer Report that highlights the biopharmaceutical companies developing new medicines and vaccines used for the treatment of cancer.

A report from PhRMA highlights how drugs that failed in clinical trials are a crucial part of development for melanoma, lung cancer, and brain cancer.

Pfizer announced that it has received FDA Priority Review for palbociclib, in combination with letrozole, as a treatment for HER2- advanced breast cancer.

IDT Biologika completes large-scale biologics finishing facility in Dessau, Germany.

Iclusig?s original indication will remain unchanged after a thorough examination of its safety information by EMA.

The European Medicines Agency releases highlights from its Pharmacovigilance Risk Assessment Committee safety review meeting in October.

Endo will acquire Auxilium Pharmaceuticals in a cash and stock transaction for approximately $2.6 billion.

CPhI released Part 3 of its annual industry report featuring three experts in the pharmaceutical industry.